COMPANY

Processa Pharmaceuticals

HQ: Vero Beach, FL source · processapharmaceuticals.com ↗ · Southeast

Keywords: neurology immunology food allergy chronic spontaneous urticaria multiple sclerosis Necrobiosis Lipoidica Duchenne Muscular Dystrophy Breast Cancer TNBC - Triple-Negative Breast Cancer HER2-negative Breast Cancer Tumor Gastric Metastatic Bladder Cancer Metastatic Pancreatic Cancer Gastroparesis PCS499 RX-3117 HT-100 PCS12852

Location: Vero Beach, FL · source · Oct 15, 2026

Profile checked Oct 10, 2026

$212.0MRaised (2 yrs)10Trials (company is sponsor)

Timeline

Jul 29, 2026 Raise Private placement: $200M (total, as published), announced Jul 29, 2026. Source: SEC filing. source ↗
Aug 7, 2025 Raise Private placement: amount not published, announced Aug 7, 2025. Source: SEC filing. source ↗
Jun 17, 2025 Raise Follow-on offering: $7M (total, as published), announced Jun 17, 2025. Source: SEC filing. source ↗
Jan 27, 2025 Raise Follow-on offering: $5M (total, as published), announced Jan 27, 2025. Source: SEC filing. source ↗
Oct 2, 2024 Trial start 2: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer source ↗
Mar 9, 2022 Trial start Phase 2: Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis source ↗
Jun 18, 2021 Trial start Phase 1: A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors source ↗
Apr 12, 2021 Trial start Phase 2: A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica source ↗
Nov 7, 2018 Trial start Phase 2: A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica source ↗
Feb 26, 2018 Trial start Phase 1: Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects source ↗
Oct 2, 2017 Trial start Phase 1/Phase 2: RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer source ↗
2013-12 Trial start Phase 1/Phase 2: Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies source ↗
2013-10 Trial start Phase 2: Open Label Extension Study of HT-100 in Patients With DMD source ↗
2013-05 Trial start Phase 1/Phase 2: Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy source ↗

Funding

Raised: $212.0M. Last 2 years.

Jul 29, 2026 Private placement: $200M (total, as published), announced Jul 29, 2026. Source: SEC filing. source ↗
Aug 7, 2025 Private placement: amount not published, announced Aug 7, 2025. Source: SEC filing. source ↗
Jun 17, 2025 Follow-on offering: $7M (total, as published), announced Jun 17, 2025. Source: SEC filing. source ↗
Jan 27, 2025 Follow-on offering: $5M (total, as published), announced Jan 27, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 10

Record	Title	Phase	Status	Start	Primary completion
NCT06568692	A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer	2	Terminated	Oct 2, 2024	Jul 29, 2026 (actual)
NCT04861987	A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors	Phase 1	Completed	Jun 18, 2021	Jun 12, 2024 (actual)
NCT02030067	Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies	Phase 1/Phase 2	Completed	2013-12	2019-07 (actual)
NCT03189914	RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer	Phase 1/Phase 2	Completed	Oct 2, 2017	Oct 1, 2019 (actual)
NCT04800562	A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica	Phase 2	Terminated	Apr 12, 2021	Feb 28, 2023 (actual)
NCT05270460	Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis	Phase 2	Completed	Mar 9, 2022	Sep 29, 2022 (actual)
NCT03698864	A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica	Phase 2	Completed	Nov 7, 2018	Feb 25, 2020 (actual)
NCT01847573	Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy	Phase 1/Phase 2	Terminated	2013-05	Mar 30, 2016 (actual)
NCT01978366	Open Label Extension Study of HT-100 in Patients With DMD	Phase 2	Terminated	2013-10	Apr 30, 2016 (actual)
NCT03836222	Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects	Phase 1	Completed	Feb 26, 2018	Jun 4, 2018 (actual)